Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort

Author:

Combe Bernard1ORCID,Rincheval Nathalie12,Berenbaum Francis3,Boumier Patrick4,Cantagrel Alain5,Dieude Philippe6,Dougados Maxime7,Fautrel Bruno8,Flipo René-Marc9,Goupille Philippe10,Mariette Xavier11,Saraux Alain12ORCID,Schaeverbeke Thierry13,Sibilia Jean14,Vittecoq Olivier15,Daurès Jean-Pierre2

Affiliation:

1. CHU Montpellier, Montpellier University

2. Biostatistics, Nouvelles Technologies et Université de Montpellier, Montpellier

3. Sorbonne Université, INSERM CRSA, AP-HP Saint Antoine Hospital, Paris

4. Amiens University Hospital, Amiens

5. Toulouse University Hospital, Toulouse

6. Université de Paris, AP-HP, Hôpital Bichat, DMU Locomotion, UMR 1152, INSERM

7. Paris-Descartes University; UPRES-EA 4058; Cochin Hospital

8. Rheumatology Department, Sorbonne Université APHP, Pierre Louis Institute of Epidemiology and Public Health INSERM UMRS 1136, Pitié Salpêtrière University Hospital, Paris

9. Lille University Hospital, Lille 2 University, Lille

10. Université de Tours, EA 7501; CHU de Tours, CIC INSERM 1415, Tours

11. Université Paris-Saclay, AP-HP, Hôpital Bicêtre, INSERM UMR1184, Le Kremlin Bicêtre

12. Brest University Hospital, Brest

13. Bordeaux University Hospital, Bordeaux

14. Strasbourg University Hospital, Strasbourg

15. Rheumatology Department, CIC-CRB 1404, Rouen University Hospital, Rouen, Normandy, France

Abstract

Abstract Objective To report the 10-year outcome of an inception cohort of patients with early rheumatoid arthritis (RA), the ESPOIR cohort, and predictors of outcome. Methods From 2003 to 2005, 813 patients were included if they had early arthritis (<6 months) with a high probability of RA and had never been prescribed DMARDs. Multivariate analysis was used to evaluate predictors of outcome. Results In total, 521 (64.1%) RA patients were followed up for 10 years; 35 (4.3%) died, which appears to be similar to the French general population. Overall, 480 (92.1%) patients received a DMARD; 174 (33.4%) received at least one biologic DMARD, 13.6% within 2 years. At year 10, 273 (52.4%) patients were in DAS28 remission, 40.1% in sustained remission, 14.1% in drug-free remission, 39.7% in CDAI remission. Half of the patients achieved a health assessment questionnaire-disability index (HAQ-DI) < 0.5. SF-36 physical component and pain were well controlled. Structural progression was weak, with a mean change from baseline in modified Sharp score of 11.0  (17.9). Only 34 (6.5%) patients required major joint surgery. A substantial number of patients showed new comorbidities over 10 years. Positivity for anti-citrullinated peptides antibodies (ACPA) was confirmed as a robust predictor of long-term outcome. Conclusions We report a very mild 10-year outcome of a large cohort of patients with early RA diagnosed in the early 2000s, which was much better than results for a previous cohort of patients who were recruited in 1993. This current favourable outcome may be related to more intensive care for real-life patients.

Funder

Merck Sharp and Dohme

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3